Herceptin and breast cancer: An overview for surgeons

Surgical Oncology

Volumn 19, Issue 1, 2010, Pages

  Patani, N ^a   Mokbel, K ^a,b  

^a Princess Grace Hospital   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Evidence; Herceptin; Morbidity; Mortality; Recurrence; Trastuzumab

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DRUG MECHANISM; HEART DISEASE; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SURGEON; SYSTOLIC DYSFUNCTION; ADJUVANT CHEMOTHERAPY; ALGORITHM; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 75849133435     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2008.11.001     Document Type: Review

References (101)

1. Mass R.D. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58 (2004) 932-940
2. Pegram M.D., Konecny G., and Slamon D.J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103 (2000) 57-75
3. Pegram M., and Slamon D. Biological rationale for HER2/neu (cerbB2) as a target for mono clonal antibody therapy. Semin Oncol 27 Suppl. 9 (2000) 13-19
4. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
5. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61 Suppl. 2 (2001) 1-13
6. Hicks D.G., and Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med 132 6 (2008 Jun) 1008-1015
7. Hicks D.G., and Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 129 2 (2008 Feb) 263-273
8. Vamesu S. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom J Morphol Embryol 48 2 (2007) 121-129
9. Shepard H.M., Lewis G.D., Sarup J.C., Fendly B.M., Maneval D., Mordenti J., et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11 3 (1991) 117-127
10. Perez E.A., and Baweja M. HER2-positive breast cancer: current treatment strategies. Cancer Invest 26 6 (2008 Jul) 545-552
11. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89 (1992) 4285-4289
12. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357 1 (2007 Jul 5) 39-51
13. Arnould L., Gelly M., Penault-Llorca F., Benoit L., Bonnetain F., Migeon C., et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 94 (2006) 259-267
14. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
15. Cooley S., Burns L., Repka T., and Miller J. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27 (1999) 1533-1541
16. Izumi Y., Xu L., di Tomaso E., Fukumura D., and Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416 (2002) 279-280
17. Lane H.A., Motoyama A., Beuvink I., and Hynes N. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 12 (2001) 21-22
18. Le X.F., Claret F.X., Lammayot A., Tian L., Deshpande D., LaPushin R., et al. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278 (2003) 23 441-23 450
19. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37 (1993) 255-263
20. Mimura K., Kono K., Hanawa M., Kanzaki M., Nakao A., Ooi A., et al. Trastuzumab-mediated antibodydependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res. 11 (2005) 4898-4904
21. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., and Baselga J. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61 (2001) 4744-4749
22. Pietras R.J., Poen J.C., Gallardo D., Wongvipat P.N., Lee H.J., and Slamon D.J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59 (1999) 1347-1355
23. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., and Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62 (2002) 4132-4141
24. Baselga J., Perez E.A., Pienkowski T., and Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 Suppl. 1 (2006) 4-12
25. Albanell J., Codony J., Rovira A., Mellado B., and Gascón P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532 (2003) 253-268
26. Ocana A., Cruz J.J., and Pandiella A. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol 29 1 (2006 Feb) 90-95
27. Mohsin S.K., Weiss H.L., Gutierrez M.C., Chamness G.C., Schiff R., Digiovanna M.P., et al. Neo-adjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23 11 (2005 Apr 10) 2460-2468
28. Henson E.S., Hu X., and Gibson S.B. Herceptin sensitizes ErbB2 overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 12 3 Pt 1 (2006) 845-853
29. Niu G., and Bradford Carter W. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 67 4 (2007) 1487-1493
30. Wen X.-F., Yang G., Mao W., Thornton A., Liu J., Bast Jr. R.C., et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25 (2006) 6986-6996
31. Valabrega G., Montemurro F., and Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18 6 (2007 Jun) 977-984
32. Nahta R., and Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 26 25 (2007 May 28) 3637-3643
33. Nahta R., and Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8 6 (2006) 215
34. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal anti body against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
35. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 19 (2005) 4265-4274
36. Perez E.A., Rowland K.M., and Suman V.J. N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer: an NCCTG randomized phase II trial. [abstr 216]. Breast Cancer Res Treat 82 (2003) S47
37. Osoba D., Slamon D.J., Burchmore M., and Murphy M. Effects on quality of life of combined trastuzu mab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20 14 (2002) 3106-3113
38. Herceptin prescribing information. Available from: (2006). www.gene.com [accessed 1.10.07]
39. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. Available from: www.nccn.org/professionals/physician_gls/PDF/breast.pdf. [accessed 1.10.07].
40. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Docetaxel and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER2- positive operative breast cancer. Combined analysis of NSABP-B-31 and NCCTGN9831. Program and abstracts of the 41st annual meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13-17, 2005, Oral presentation during symposium, advances in monoclonal antibody therapy for breast cancer.
41. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
42. Perez E.A., Romond E.H., and Suman V.J. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25 Suppl. 18 (2007) 512
43. Slamon D., Eiermann W., and Robert N. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: second interim efficacy analysis. Breast Cancer Res Treat 100 Suppl. 1 (2006) 53
44. Piccart-Gebhart MJ, The Breast International Group. Advances in monoclonal antibody therapy for breast cancer. HERA trial. Program and abstracts of the 41st annual meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13-17, 2005.
45. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
46. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
47. Viani G.A., Afonso S.L., Stefano E.J., De Fendi L.I., and Soares F.V. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7 (2007 Aug 8) 153
48. Bria E., Nistico C., Cuppone F., Carlini P., Ciccarese M., Milella M., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106 11 (2006) 2337-2344
49. Burstein H.J., Harris L.N., German R., and Lester S.C. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21 1 (2003) 46-53
50. Harris L.N., Burstein H.J., and German R. Preoperative trastuzumab and vinorelbine is highly active, well-tolerated regimen for HER2 3+/FISH + stage II/III breast cancer. [abstr 86]. Proc Am Soc Clin Oncol 22 (2003) [abstract no. 86]
51. Hurley J., Dolina P., and Silva O. Neo-adjuvant herceptin/taxotere/cisplatin in the treat ment of locally advanced and inflammatory breast cancer. [abstr 196]. Proc Am Soc Clin Oncol 21 (2002) [abstract no. 196]
52. Van Pelt A.E., Mohsin S., Elledge R.M., Hilsenbeck S.G., Gutierrez M.C., Lucci Jr. A., et al. Neo-adjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4 (2003) 348-353
53. Limentani S.A., Brufsky A.M., Erban J.K., Jahanzeb M., Lewis D., et al. Dose-dense neo-adjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Breast Cancer Res Treat 82 (2003) S55
54. Carey LA, Dees EC, Sawyer L. Response to trastuzumab given with paclitaxel immediately following 4AC as initial therapy for primary breast cancer. Proceedings of the 24th San Antonio breast cancer symposium; 2002.
55. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neo-adjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2- positive operable breast cancer. J Clin Oncol 23 16 (2005) 3676-3685
56. Gianni L., Semiglazov V., Manikhas G.M., Eiermann W., Lluch A., Tjulandin S., et al. Neo-adjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumor and safety analysis. J Clin Oncol 25 (2007) 18S [abstract 532]
57. Lazaridis G., Pentheroudakis G., and Pavlidis N. Integrating trastuzumab in the neo-adjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol 66 1 (2008 Apr) 31-41
58. Tripathy D., Slamon D.J., Cobleigh M., Arnold A., Saleh M., Mortimer J.E., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22 6 (2004) 1063-1070
59. Von Minckwitz G., Zielinski C., Maarteense E., Vogel P., Schmidt M., Eidtmann H., et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol 26 May 20 Suppl. (2008) [abstr 1025]
60. Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 5 (2002) 1215-1221
61. Theodoulou M., Campos S.M., and Batist G. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 21 (2002) 55a
62. Ewer M.S., Vooletich M.T., Durand J.B., Woods M.L., Davis J.R., Valero V., et al. Reversibility of trastuzumab related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 31 (2005) 7820-7826
63. Ewer M.S., and Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23 (2005) 2900-2902
64. Herceptin (Trastuzumab) package insert, HER2 package insert (January 2000), Genetech, Inc., USFDA
65. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, et al. Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Program and abstracts of the 28th annual San Antonio breast cancer symposium, San Antonio, Texas; 2005 [abstr 2038].
66. Suter T.M., Procter M., van Veldhuisen D.J., Muscholl M., Bergh J., Carlomagno C., et al. Trastuzumab associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25 (2007 Jul 23) 3859-3865
67. Bria E., Cuppone F., Fornier M., Nisticò C., Carlini P., Milella M., et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109 2 (2008 May) 231-239 [Epub 2007 Jul 19]
68. Rastogi P., Jeong J., and Geyer C.E. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)_paclitaxel (T) vs. AC_T with trastuzumab (H). J Clin Oncol 25 Suppl. 18 (2007) 513
69. Tan-Chiu E., Yothers G., Romond E., Geyer Jr. C.E., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 (2005) 7811-7819
70. Geyer C.E., Bryant Jr. J.L., Romond E.H., Ewer M.S., Keefe D.L., Shannon R.P., et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs. ACT with trastuzumab (H). J Clin Oncol 24 Suppl. 18 (2006) 581
71. Tripathy D., Seidman A., Keefe D., Hudis C., Paton V., Lieberman G., et al. Effect of cardiac dysfunction on treatment out comes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 5 4 (2004) 293-298
72. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 95 (2002) 1592-1600 [Erratum, Cancer 2003;97:1136.]
73. Bast Jr. R.C., Ravdin P., Hayes D.F., Bates S., Fritsche Jr. H., Jessup J.M., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 6 (2001) 1865-1878
74. Gown A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21 Suppl. 2 (2008 May) S8-S15
75. Wang S., Saboorian M.H., Frenkel E., Hynan L., Gokaslan S.T., Ashfaq R., et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 53 (2000) 374-381
76. Pauletti G., Dandekar S., Rong H., Ramos L., Peng H., Seshadri R., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18 (2000) 3651-3664
77. Mass R.D., Press M., Anderson S., Murphy M., and Slamon D. Improved survival benefit from herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 20 (2001) 22a [abstract]
78. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., and Schnitt S.J. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17 7 (1999) 1974-1982
79. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., et al. Real-world performance of HER2 testing-national surgical adjuvant breast and bowel project experience. Natl Cancer Inst 94 11 (2002) 852-854
80. Perez E.A., Suman V.J., Davidson N.E., Martino S., Kaufman P.A., Lingle W.L., et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol 24 (2006) 3032-3038
81. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allr66ed D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131 (2007) 18
82. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
83. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
84. Kaufman P.A., Broadwater G., and Lezon-Geyda K. CALGB 150002: correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2_ and HER2- metastatic breast cancer (MBC). J Clin Oncol 25 Suppl. 18 (2007) 1009
85. Paik S., Kim C., and Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358 13 (2008 Mar 27) 1409-1411
86. Paik S., Kim C., Jeong J., Geyer C.E., Romond E.H., Mejia-Mejia O., et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: central testing results from NSABP B-31. J Clin Oncol 25 (2007) 18S [Abstr 511]
87. Vanden Bempt I., Drijkoningen M., and De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 19 6 (2007 Nov) 552-557
88. Press M.F., Bernstein L., Sauter G., Zhou J.Y., Eiermann W., Pienkowski T., et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracyline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. [abstract no. 1045]. Breast Cancer Res Treat 94 Suppl. 1 (2005) S54
89. Kim C., Bryant J., Horne Z., Geyer C.E., Wickerham D.L., Wolmark N., et al. Trastuzumab sensitivity of breast cancer with coamplification of HER2 and cMYC suggests proapoptotic function of dysregulated cMYC in vivo. Cancer Cell 5 4 (2004) 317-328
90. Paik S., Bryant J., Park C., Fisher B., Tan-Chiu E., Hyams D., et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90 (1998) 1361
91. Järvinen T.A., Tanner M., Rantanen V., Bärlund M., Borg A., Grénman S., et al. Amplification and deletion of topoisomerase I alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156 3 (2000) 839-847
92. Munshi A., Singh P., and Jalali R. Trastuzumab: is the new evidence revolutionary?. J Cancer Res Ther 2 3 (2006 Jul-Sep) 144-146
93. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 355 (2000) 1757-1770
94. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 366 (2006) 2087-2106
95. Cuzick J., Stewart H., Rutqvist L., Houghton J., Edwards R., Redmond C., et al. Cause specific mortality in long term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12 (1994) 447-453
96. Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group Phase III trial N9831, 24; 2006, p. 523.
97. Bendell J., Domchek S., Burstein H., Harris L., Younger J., Kuter I., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
98. Clayton A., Danson S., Jolly S., Ryder W., Burt P., Stewart A., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91 (2004) 639-643
99. Lin N., Bellon J., and Winer E. CNS metastases in breast cancer. J Clin Oncol 22 (2004) 3608-3617
100. Pestalozzi B., and Brignoli S. Traztuzumab in CSF. J Clin Oncol 18 (2000) 2350-2351
101. Pal S.K., and Pegram M. HER2 targeted therapy in breast cancer beyond herceptin. Rev Endocr Metab Disord 8 3 (2007 Sep) 269-277